Strategic alliance fast tracking screening of drug discovery targets.
Perth, Australia, February 23, 2011: – Australian drug discovery company Phylogica Ltd (ASX:PYC), ( XETRA PH7) and UK company Isogenica Ltd have succeeded in a proof of
concept project demonstrating compatibility of Isogenica’s proprietary CIS in-vitro display technology for peptide engineering and drug discovery with Phylogica’s Phylomer® drug
discovery platform.
Phylogica scientists are now confident that using the display technology will ensure accelerated screening of the company’s vast Phylomer libraries to meet demand from
potential pharmaceutical partners.
Isogenica has been successful in hitting all milestones to date related to the collaboration, which was announced in January 2010.
For further information please download the below PDF.
